Senti Biosciences, Inc. (SNTI): Nasdaq/NYSE listing notice — Senti Biosciences Transfers to Nasdaq Capital Market, Gets Second Compliance Period

Senti Biosciences, Inc.

On Jan 23, 2024, Nasdaq approved transfer of Senti Biosciences common stock from Global Market to Capital Market, effective Jan 25.
Nasdaq granted a second 180-day period until Aug 5, 2024, to meet $1.00 bid price requirement.
Company must show closing bid price >= $1.00 for 10 consecutive business days to regain compliance.
If not compliant by Aug 5, 2024, Nasdaq will delist SNTI; company may appeal to Hearings Panel.
Senti Biosciences intends to consider a reverse stock split to cure the bid price deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Senti Biosciences, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

February 6, 2024, the Staff granted the Company’s request for a second 180-calendar day period, or until August 5, 2024 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The transfer of the listing of the Company’s Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market took effect with the open of business on Ja

View on SEC.gov

Browse all listing & compliance notices →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-24-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.